Overview of Prodolina

Property	Description
Active Ingredient	Dipyrone / Metamizole sodium
Form	Tablet, Injection, Solution, Suppository
Pharmacological Class	Non-opioid Analgesic, Antipyretic, Spasmolytic
General Purpose	Relief from moderate-to-severe pain, fever, and spasm
Origin	Synthetic organic (Pyrazolone derivative)

1. Identity, Classification, and Composition

Prodolina is the medicinal entity for the compound Dipyrone, formally known by its International Nonproprietary Name (INN) of Metamizole or its sodium salt, Metamizole sodium. It is classified as a potent non-opioid analgesic, a distinct antipyretic, and an effective spasmolytic agent. This classification highlights its multi-faceted approach to symptomatic relief. The compound is a synthetic organic compound derived from the pyrazolone chemical family, a unique characteristic that differentiates it chemically from common over-the-counter pain relievers. The substance acts as a prodrug, converting into active metabolites like 4-methyl-amino-antipyrine within the body.

2. General Purpose and Therapeutic Profile

The primary function of Prodolina is to provide multi-modal symptomatic relief by targeting pain, fever, and spasm simultaneously. Its therapeutic profile is utilized for effectively diminishing moderate-to-severe pain and reducing high, persistent fever. The substance is clinically recognized for its anti-spasm effect, which is particularly useful in managing acute pain associated with involuntary contractions of smooth muscles, such as those that characterize renal or biliary colic. It functions as a strong pain reliever that operates centrally in the nervous system. Metamizole acts on central and peripheral pain pathways to manage acute pain.

3. Pharmaceutical Forms of Prodolina

Prodolina is manufactured in a variety of pharmaceutical presentations to facilitate flexible routes of administration. These forms include standard oral solid preparations (tablets, capsules) and oral liquid preparations (drops, solutions), often used for managing fever or moderate acute pain. For situations requiring immediate onset or when oral intake is compromised, the drug is also available as parenteral preparations (injectable solutions) for intramuscular or intravenous use. The availability of the injectable form is a key feature, supporting its use in clinical settings where rapid, reliable relief is essential.

Therapeutic Uses of Prodolina

Prodolina (Metamizole) is commonly used for symptomatic relief, addressing symptoms related to heightened physiological activity across three primary therapeutic domains. It is utilized for acute moderate-to-severe pain of post-operative, post-traumatic, or colic origin, as well as high fever that does not respond to other therapeutic measures.

The medication is considered relevant in conditions presenting with systemic or localized discomfort and may be used when supportive symptom management is appropriate, particularly in clinical settings that involve acute or unstable symptom patterns. It may assist with easing symptoms related to muscle cramping and contributes to improved comfort during periods of heightened discomfort.

“This medication is applied in situations where additional symptomatic support is needed for managing challenging manifestations like severe pain and high fever.”

Relief from Acute, Moderate-to-Severe Pain

Prodolina is generally used to help address symptom clusters that create noticeable physiological strain, specifically symptoms related to moderate-to-severe pain. It is commonly applied in clinical settings that involve acute or disruptive pain patterns, such as those following surgery or trauma. The medication provides supportive relief that helps ease the overall symptom burden.

Quick Fact: Relief for Spasmodic Visceral Pain

The medication is commonly used to help manage acute symptoms linked to organ-specific functional stress, such as renal or biliary colic.

Regulatory References

AEMPS Technical Sheet on Metamizol

Eligibility and Restrictions for Use

Prodolina (Metamizole) eligibility is strictly defined by government regulatory documents, outlining which populations are permitted to use the medicine and which are absolutely prohibited.

Contraindicated Populations

The medicine must not be used by patients with a history of agranulocytosis induced by pyrazolones or with impaired bone marrow function. Use is also contraindicated in patients with certain metabolic conditions, such as acute intermittent hepatic porphyria or genetic G6PD deficiency, and in those with known analgesic-induced asthma syndrome.

Age- and Physiological Status

The medicine is contraindicated in infants below three months of age or those weighing less than 5 kg. Use is also contraindicated during the third trimester of pregnancy. In the first two trimesters, a single dose may be acceptable if other pain relievers cannot be used. Prodolina is not recommended while breastfeeding; if administered, breast milk should be discarded for 48 hours.

Conditional Use and Restrictions

Adults and adolescents aged 15 years and older are generally eligible. Use in children is weight-based, but fixed-dose tablets are often not recommended for younger children. Patients with severe hepatic or renal impairment must avoid multiple high doses due to the potential for prolonged elimination of metabolites. The medicine is also contraindicated in patients with arterial hypotension or an unstable circulatory state.

What should I know about interactions with other medicines?

The official regulatory profile for Prodolina (Metamizole) primarily details pharmacokinetic and pharmacodynamic interactions that impose specific administration constraints.

Contraindicated Combination

Co-administration is classified as contraindicated with other substances in the pyrazolone or pyrazolidine chemical classes for patients with a history of agranulocytosis caused by these drugs.

Pharmacokinetic Interactions

Metamizole's active metabolites are documented to be enzyme inducers, primarily of CYP2B6 and CYP3A4. This pharmacokinetic interaction results in a documented reduction in the plasma concentrations of co-administered medicines that are substrates for these enzymes. Officially listed examples include the immunosuppressants Cyclosporine and Tacrolimus, and the antidepressant Bupropion.

Administration Timing Rule

A timing-based interaction rule exists for low-dose Acetylsalicylic Acid (Aspirin) used for vascular protection. Metamizole must be administered at least two hours after Aspirin to prevent the documented interference with Aspirin's anti-platelet effect.

Pharmacodynamic Effects

Officially documented additive risks include a potential increase in the hematological toxicity of Methotrexate and a possible risk of severe hypothermia when co-administered with Chlorpromazine. Furthermore, Prodolina may potentiate the effects of alcohol.

Mechanism of Action

Prodolina functions as a prodrug, which is rapidly hydrolyzed in the gastrointestinal tract and liver into its primary active metabolites, 4-methylaminoantipyrine (MAA) and 4-aminoantipyrine (AA), which cross the blood-brain barrier.

The mechanism involves multiple targets within the central nervous system (CNS). The active metabolites act as inhibitors of the cyclooxygenase enzyme COX-3 isoform, which is predominantly expressed in the brain and spinal cord, resulting in a modulation of central prostaglandin E2 synthesis, specifically in the hypothalamic thermoregulatory center. This decreased prostaglandin synthesis modulates central thermoregulation and nociceptor sensitivity.

Furthermore, the metabolites engage with the endogenous opioid system and the cannabinoid system. MAA and AA are proposed to exhibit agonism at cannabinoid type 1 (CB1) receptors and may modulate the release or levels of endogenous opioids, leading to a synergistic inhibitory effect on ascending nociceptive signaling pathways.

Dosage and Administration Information

How to Use Prodolina

The usage of Prodolina (Metamizole/Dipyrone) is defined by established means of administration, dose limits, and timing intervals. These parameters ensure consistent and controlled use.

Routes and Forms of Administration

Prodolina is available for several administration routes:

Oral: Available as tablets, capsules, and solutions/drops.
Parenteral: Used as a solution for intravenous (IV) or intramuscular (IM) injection/infusion.
Rectal: Available as suppositories for administration.

Dosing and Frequency Guidelines

The dosage and frequency of use emphasize using the lowest effective dose to control symptoms.

Usage Feature	Adult Regimen (Ages 15 and older)	Context
Maximum Single Oral Dose	Up to 1,000 mg (1 g)	Standard maximum single intake.
Maximum Daily Oral Dose	4,000 mg (4 g)	Total daily dose limit.
Dosing Interval	A minimum of 6 to 8 hours between doses.	Required time separation to prevent overexposure.

Special Administration Conditions

For pediatric patients (up to 14 years), dosing is based on body weight (BW), with a typical single dose range of 8 to 16 mg/kg BW. Specific procedural constraints exist for clinical administration: intravenous injection is performed slowly, typically at a rate not exceeding 50 mg/minute, to ensure controlled delivery of the drug. Prodolina is primarily intended for short-term use for acute symptom management, although use duration may be extended in specific conditions under professional guidance.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Prodolina (Metamizole)

Prodolina (Metamizole) was studied for short-term uses reflected in its research base. The evidence base primarily consists of Randomized Controlled Trials (RCTs) and Systematic Reviews that combine the results of multiple studies. This research contributes to the broader evidence landscape by examining how symptoms change over defined time intervals.

Evidence for Use in Acute, Moderate-to-Severe Pain

Research explored how Prodolina was studied for acute pain following surgical procedures in adult patients. Studies examined outcomes related to patient-reported discomfort and the need for rescue medication over short, acute follow-up durations. The evidence so far describes patterns related to these episodic changes, though many individual trials had modest sample sizes, and follow-up durations were limited.

Evidence for Pain of Acute Colic Origin

Prodolina was studied for use in conditions characterized by functional limitations such as pain from renal or biliary colic. Research focused on examining acute changes in pain intensity over very rapid time intervals, primarily in adult patients. The certainty remains low for this indication, however, due to a limited number of trials, small participant numbers, and heterogeneity across the available studies.

Evidence for Use in Reducing High Fever (Antipyresis)

Research examined Prodolina as an agent for outcomes related to systemic imbalance, specifically persistent high fever. Studies monitored changes in body temperature and compared response patterns to that of other common antipyretics in both febrile children and adult patients. Findings describe patterns observed in these settings, though high heterogeneity in results and a focus exclusively on the acute temperature response limit the evidence.

Evidence in Specific Populations and Long-Term Follow-up

Research evaluated Prodolina in a range of populations, including studies exploring its use in children for fever management and in older adults for postoperative pain. However, most clinical trials focused on short-term or episodic symptom patterns, and therefore, long-term effects are not fully established through controlled trials.

Research Gaps and What Remains Uncertain

The evidence highlights what is known—and what is still uncertain. Across all indications, the follow-up durations were limited, contributing to a lack of data on long-term outcomes. Comparative evidence is lacking for some key clinical scenarios, and data for certain subgroups remain insufficient, meaning the results apply only to the specific populations studied.

Frequently Asked Questions (FAQ)

Common questions about Prodolina (FAQ)

Q: Can Prodolina be taken long-term?

A: Official product information notes that Prodolina is primarily intended for short-term use to manage acute symptoms like pain and fever. Due to limited experience and data from clinical trials regarding long-term exposure, regulatory documents generally advise using the medicine for the shortest duration possible.

Q: Is it okay to take Prodolina if I occasionally drink alcohol?

A: Regulatory documents state that Prodolina may potentiate the effects of alcohol. This means the effect of alcohol may be increased or prolonged while the medicine is in your system. The official documentation suggests caution when using Prodolina with alcohol.

Q: What is the typical length of treatment with Prodolina?

A: Prodolina is typically used for short-term, acute symptom management, such as treating high fever or severe pain episodes. Official instructions for certain routes may specify a maximum duration, aligning with its general short-term role.

Q: Is Prodolina safe for people who have kidney issues?

A: Patients with impaired or reduced kidney function may eliminate the active metabolites of Prodolina more slowly. Because of this, official documents advise that multiple high doses must be avoided in cases of severe kidney impairment. For short-term use, the need for dose adjustments is determined based on the degree of impairment.

Q: Is Prodolina safe for people with liver disease?

A: The active substance in Prodolina is processed by the liver, and elimination can be slower in patients with reduced liver function. Regulatory information therefore states that multiple high doses must be avoided in severe liver impairment. The application of Prodolina is generally limited to short-term use.

Q: Does Prodolina interact with birth control pills?

A: Prodolina is documented as an inducer of certain liver enzymes, including CYP2B6 and CYP3A4. Medicines that rely on these enzymes for processing, such as certain hormonal contraceptives, may have their plasma concentration reduced. The official documentation indicates this interaction may result in lower circulating levels of the contraceptive.

Q: Does Prodolina need to be taken at a specific time of day?

A: Prodolina does not require a fixed time of day for administration, but official guidelines mandate a minimum time separation of at least 6 to 8 hours between doses to avoid overexposure. Additionally, if you take low-dose aspirin for vascular protection, regulatory documents specify that Prodolina must be taken at least two hours after the aspirin to prevent potential interference.

Q: Can I stop taking Prodolina suddenly if I feel better?

A: Prodolina is generally intended for short-term use, but patients are instructed to immediately discontinue treatment if signs of a serious blood disorder, such as persistent fever or sore throat, appear. Cessation guidance for non-emergency situations is typically determined by a health professional.

Q: Is it normal to have certain mild side effects when starting Prodolina?

A: Official regulatory documents list several reactions as common side effects, including nausea, vomiting, and headache. These are considered expected occurrences during treatment. While the product information doesn't explicitly confirm the 'normality' of experiencing these at the start of treatment, their classification as common effects suggests they are frequently observed.

Q: Can Prodolina be used by people with a history of heart problems?

A: Regulatory documents indicate that Prodolina is contraindicated (should not be used) in patients with a history of arterial hypotension (low blood pressure) or an unstable circulatory state. Other specific heart conditions require review to determine eligibility.

Q: How quickly should I expect to notice any effects from Prodolina?

A: The onset of action varies based on the form of administration. According to regulatory pharmacokinetics data, a clear analgesic effect can be expected 30 to 60 minutes after oral administration. For solutions administered via injection, the effect is expected after approximately 30 minutes.

Q: Is Prodolina a controlled substance?

A: Prodolina is not generally classified as a controlled substance in the jurisdictions where it is approved and actively marketed (e.g., in much of the EU and parts of South America). However, its regulatory classification varies significantly by country, being either unapproved, restricted, or withdrawn in numerous countries, including the US, UK, and Canada.

Q: How long does Prodolina stay in your system?

A: The half-life of the active metabolites of Prodolina is documented to be between 2 to 10 hours. Due to the presence of these metabolites in breast milk, official advice is that women using the medicine should discard breast milk for 48 hours after administration.

Q: Does Prodolina require special monitoring or blood tests?

A: Official regulatory information advises that patients be monitored for signs of blood disorders, such as the rare but serious side effect of agranulocytosis. Monitoring for symptoms like persistent fever, sore throat, or mucosal inflammation is necessary. The medicine is also contraindicated if the patient has pre-existing issues with bone marrow function.

Q: Is Prodolina intended to be a cure, or just a management tool?

A: Prodolina is officially classified as an analgesic (pain-reliever), antipyretic (fever-reducer), and spasmolytic (spasm-reducer). These are therapeutic actions focused on the symptomatic treatment of pain, fever, and spasm, meaning it is used for managing symptoms rather than curing the underlying condition.

Q: How does Prodolina affect one's ability to concentrate?

A: The SmPC includes a dedicated section on the Effects on ability to drive and use machines. It states that while no such effects are known at recommended doses, it is advisable to avoid operating machines or driving if higher doses are used or if any central nervous system effects are experienced.

Q: Is Prodolina an antidepressant?

A: No, regulatory documents classify Prodolina as a non-opioid analgesic, antipyretic, and spasmolytic. It does not belong to the pharmacological class of antidepressants.

Q: Are there specific symptoms that mean Prodolina is working?

A: Prodolina is used for the reduction of pain, fever, and spasm. The first indication that the medicine is working is the experience of relief from these specific symptoms, which is typically noted 30 to 60 minutes after oral administration.

Q: Can Prodolina make people feel dizzy or lightheaded?

A: Yes, official regulatory documents list dizziness as a documented side effect. Additionally, the risk of hypotension (low blood pressure) is also documented, which can contribute to lightheadedness.

Q: Can Prodolina affect fertility or reproductive health?

A: Regulatory documents contain a specific section on fertility, pregnancy, and breast-feeding. The official product information generally states that there are no studies documenting negative effects on fertility. Its use during pregnancy is contraindicated in the third trimester, and specific advice is given for the first two trimesters.

How should Prodolina be stored and disposed of?

Storage Conditions

Regulatory requirements mandate that Prodolina must be stored out of the sight and reach of children to prevent accidental exposure. Storage environments are strictly controlled: the medicine must not be refrigerated or frozen. For certain liquid preparations, there is a specific temperature restriction; for instance, some post-opening shelf-lives require storage not above 25^circC. The solution for injection must also be stored protected from light, typically by keeping it in the original container.

Stability and Handling

Once certain multi-dose vials are first opened, the product is typically restricted to an in-use stability period of 28 days. Any dilution or reconstitution must be administered immediately.

Disposal Requirements

All unused or expired Prodolina and waste materials must be disposed of in accordance with local requirements. Official guidelines advise against allowing the product to enter sewers, surface water, or ground water.

Category	Documented Risks
Serious / Life-Threatening	Agranulocytosis (incidence is rare, but can be life-threatening), acute liver failure, acute hepatitis, anaphylactic shock, Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and myelotoxicity.
Common Side Effects	Nausea, vomiting, headache, rash, hypotension, and gastrointestinal discomfort.
System-Organ Classes	Adverse events primarily affect the Blood and Lymphatic System, Immune System, Skin, Hepatobiliary System, and Renal/Urinary System.

Prodolina